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MicrodeletionEpisodic falling syndrome (EFS) is a canine paroxysmal hypertonicity disorder found in Cavalier King Charles
spaniels. Episodes are triggered by exercise, stress or excitement and characterized by progressive
hypertonicity throughout the thoracic and pelvic limbs, resulting in a characteristic 'deer-stalking' position
and/or collapse. We used a genome-wide association strategy to map the EFS locus to a 3.48 Mb critical
interval on canine chromosome 7. By prioritizing candidate genes on the basis of biological plausibility, we
found that a 15.7 kb deletion in BCAN, encoding the brain-speciﬁc extracellular matrix proteoglycan brevican,
is associated with EFS. This represents a compelling causal mutation for EFS, since brevican has an essential
role in the formation of perineuronal nets governing synapse stability and nerve conduction velocity.
Mapping of the deletion breakpoint enabled the development of Multiplex PCR and Multiplex Ligation-
dependent Probe Ampliﬁcation (MLPA) genotyping tests that can accurately distinguish normal, carrier and
affected animals. Wider testing of a larger population of CKCS dogs without a history of EFS from the USA
revealed that carriers are extremely common (12.9%). The development of molecular genetic tests for the EFS
microdeletion will allow the implementation of directed breeding programs aimed at minimizing the number
of animals with EFS and enable conﬁrmatory diagnosis and pharmacotherapy of affected dogs.tics and Biochemistry, Clemson
Pharmacology, The School of
robert.harvey@pharmacy.ac.uk
irect.com).
license.© 2011 Elsevier Inc. Open access under CC BY license.Introduction
Episodic falling syndrome (EFS) is a well-recognized paroxysmal
disorder found in Cavalier King Charles spaniels (CKCS). Episodes
begin between fourteen weeks and four years of age and are triggered
by exercise, stress, apprehension or excitement (Herrtage and Palmer,
1983). Episodes are of variable frequency and severity but are
characterized by progressive hypertonicity involving thoracic and
pelvic limbs (Fig. 1a) until the dogs are ultimately immobilized in a
characteristic 'deer-stalking' or 'praying' position (Fig. 1b). Stiffening
of all four limbs during exercise can cause falling (Fig. 1c), although
there is no loss of consciousness or cyanosis. Other clinical signs may
include facial muscle stiffness, stumbling, a 'bunny-hopping' gait,
arching of the back or vocalization. Curiously, between episodes, dogs
appear to be completely normal neurologically. Spontaneous activitywas not observed in muscle electrodiagnostic testing, ruling out
myotonia congenita (Wright et al., 1986, 1987). Muscle biopsies are
typically normal at the light microscopic level, excluding many
congenital myopathies. However, EFS has been linked to ultrastruc-
tural defects in skeletal muscle including dilatation and proliferation
of the sarcoplasmic reticulum, mitochondrial swelling and degener-
ation (Wright et al., 1986, 1987). EFS has also been compared
(Rusbridge, 2005) with startle disease/hyperekplexia, typically
characterized by noise- or touch-evoked neonatal hypertonicity due
to defects in inhibitory glycine receptor (GLRA1, GLRB; Shiang et al.,
1993; Rees et al., 2002) or glycine transporter GlyT2 (SLC6A5) genes
(Rees et al., 2006; Harvey et al., 2008). However, a microdeletion in
the GlyT2 gene in Irish Wolfhounds results in severe neonatal muscle
stiffness and tremor in response to handling (Gill et al., 2011), which
is inconsistent with the observed clinical signs of EFS. Comparisons
with startle disease may have been made because affected dogs often
respond well to the benzodiazepine clonazepam (Garosi et al., 2002),
an effective anticonvulsant, anxiolytic and muscle relaxant that is the
most effective known treatment for human hyperekplexia (Thomas et
al., 2010). However, the carbonic anhydrase inhibitor acetazolamide,
used to treat certain types of human episodic ataxia (Tomlinson et al.,
2009) and hyperkalemic periodic paralysis (Matthews and Hanna,
Fig. 1. Clinical signs of episodic falling syndrome and muscle pathology. A 5-month-old female Cavalier King Charles spaniel presented with typical episodes of excitement or
exercise-induced muscle stiffness (a, hypertonicity) that would involve all four limbs and progress to an usual 'deer-stalking' or 'praying' posture (b), eventually resulting in falling
(c). While EFS muscle was normal histologically by light microscopy, electron microscopy (d) revealed that the sarcoplasmic reticulum (sr) appeared dilated and contained ﬁnely
granular material compared to control muscle (e). Mitochondria (m) and myoﬁbrils were normal in appearance in both tissues. Scale bars=0.31 μm.
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(http://www.cavalierhealth.org/episodic_falling).
Since a ten-year breeder-led investigation into the inheritance of EFS
suggested an autosomal recessive mode of inheritance (http://
cavalierepisodicfalling.com/), we used a genome-wide association
strategy (Karlsson et al., 2007) to map the EFS locus to a deﬁned region
of canine chromosome7. Candidate gene analysis enabledus to identify a
microdeletion affecting the brevican gene (BCAN), conﬁrm the deletion
breakpoint and develop rapid genotyping tests for EFS.
Materials and methods
Light and electron microscopy
For light microscopy, unﬁxed biopsies from the biceps femoris,
vastus lateralis and triceps brachii muscles were collected from ﬁve
affected CKCS dogs under general anesthesia and frozen in isopentane
pre-cooled in liquid nitrogen. Cryosections were cut (8 μm) and the
following histochemical stains and reactions performed: hematoxylin
and eosin, modiﬁed Gomori trichrome, periodic acid Schiff, phos-
phorylase, esterase, ATPase reactions at pH of 9.8 and 4.3, nicotin-
amide adenine dinucleotide-tetrazolium reductase, succinic
dehydrogenase, acid phosphatase, alkaline phosphatase and oil red
O. For electron microscopy, glutaraldehyde-ﬁxed muscle specimens
were post-ﬁxed in osmium tetroxide, and dehydrated in serial alcohol
solutions and propylene oxide prior to embedding in araldite resin.
Thick sections (1 μm) were stained with toludine blue for lightmicroscopy and ultrathin sections (60–90 nm) were stained with
uranyl acetate and lead citrate for electron microscopy.
Study cohort and DNA preparation
Our study cohort comprised: EFS affected—10 animals (6 from the
USA, 2 from New Zealand and 2 from the UK); Obligate EFS carriers—
8 animals (2 from the USA, 6 from New Zealand); Animals related to
carriers or affected dogs—21 animals (7 from the USA, 14 from New
Zealand); Controls—CKCS with no EFS history—14 animals (all from
the USA). Genomic DNAwas isolated fromwhole blood or buccal cells
using the Gentra Puregene Blood Kit (QIAGEN, Valencia, USA).
Additional DNA samples from 155 CKCS with no clinical history of
EFS and other pure bred-dogs were available from unrelated studies
and other sources (e.g. Cornell Medical Genetic Archive: http://www.
vet.cornell.edu/research/dnabank/).
Genome-wide association mapping
ThirteenCKCS genomicDNA samples isolated fromblood (ﬁve cases,
one obligate carrier and seven controls from the USA) were genotyped
for 127,000 SNPs on the Affymetrix Canine SNP Array version 2 (http://
www.broadinstitute.org/mammals/dog/caninearrayfaq.html). The two
main drivers for sample selection were: i) lack of relatedness—i.e., that
the animals used for case-control analysis should not share a common
ancestor within at least three generations and ii) the quality and
quantity of genomic DNA available. Arrays were processed at the
Fig. 2. Mapping the episodic falling syndrome locus. (a) –log10 of Praw values (Y axis) for
genome-wide association using ﬁve EFS and seven control dogs are plotted for each
chromosome (X axis). A singlemajor signalwasdetected on chromosome7. (b)A 3.48 Mb
critical interval encompassing SNP 43389066 is deﬁned by recombination events in an
affected CKCS and an obligate carrier.
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edu/) using the GeneChip human mapping 250 K Sty assay kit
(Affymetrix, Santa Clara, USA). The GeneChip human mapping 500 K
assay protocol was followed, but with a hybridization volume of 125 μl
(Karlsson et al., 2007). Raw CEL ﬁles were genotyped using Affymetrix
Power Tools software. SNPs having N10% missing data and ≥60%
heterozygosity were removed. Data for 58,873 SNPswere formatted for
PLINK (Purcell et al., 2007) and case/control analyses with 100,000
permutations were performed for ﬁve cases and seven controls (the
obligate carrier was excluded from analysis).
PCR and DNA sequencing
PCR primers were designed to amplify exons and ﬂanking splice
donor, acceptor and branch-point sites, from gene structures derived
in silico using the UCSC Genome Browser. For exon-speciﬁc primers
for BCAN and HAPLN2 exon ampliﬁcation see Table S1. PCR was
performed using 50 ng genomic DNA as template and AccuPrime Pfx
SuperMix supplemented with betaine for 40 cycles of 94 °C for 1 min,
60 °C for 1 min, 68 °C for 1 min. PCR products were gel puriﬁed using a
QiaQuick gel extraction kit (QIAGEN, Crawley, UK) for TOPO cloning
(pCR4Blunt-TOPO; Invitrogen, Renfrew, UK). Sanger DNA sequencing
was performed by DNA Sequencing & Services (MRCPPU, College of
Life Sciences, University of Dundee, Scotland) using Applied Biosys-
tems Big-Dye version 3.1 chemistry on an ABI 3730 automated
capillary DNA sequencer. DNA sequences were analyzed using
Sequencher 4.10 (Gene Codes Corporation, Ann Arbor, USA). For
multiplex PCRs, the diagnostic primer set is: EFS1 5′-aaggtcttacacctg-
caatgaatag-3′, EFS2 5′-agcaaatgtaaagtcctgtgaccat-3′ and EFS3 5′-
agttcacattgtgctctctctactg-3′.
Multiplex ligation-dependent probe ampliﬁcation (MLPA) analysis
FiveMLPA probe sets were designed corresponding to the promoter
region (PR) and exons 1 (5′UTR), 2, 3 and 4 of the canine brevican gene
(BCAN; NC_006589 on chromosome 7; Table S2). Criteria for MLPA
probe design were as previously described (Schouten et al., 2002). A
control probe pair was designed to recognize an unrelated gene (CFTR:
NC_006596 on chromosome 14). Probes generated ampliﬁcation
products ranging in size from 88 to 115 bp and had annealing
temperatures higher than 70 °C as recommended in RAW Probe
software (MRC-Holland, Amsterdam, The Netherlands) using standard
MLPAconditions (Schoutenet al., 2002). PCRproductswereanalyzedon
anABI 3130XL capillary electrophoresis apparatus (Applied Biosystems,
Lennik, Belgium). Normalization of BCAN-speciﬁc probe signals was
performedbydividing thevalues obtainedby the combined signal of the
control probes.
Results
Light and electron microscopy
Unﬁxed cryosections of muscle biopsies were histologically
normal at the light microscopic level with no abnormalities detected
following any of the histochemical stains and enzyme reactions
employed. Contrary to previous reports (Wright et al., 1986, 1987)
electron microscopy revealed normal myoﬁbrillar and mitochondrial
morphology, although swelling of the sarcoplasmic reticulum was
conﬁrmed (Figs. 1d,e).
Genome-wide association mapping and candidate gene resequencing
A total of 17 single nucleotide polymorphisms (SNPs)were associated
withEFS (Prawvalues≤0.0001) (Table S3). Themost signiﬁcant resultwas
for SNP 43389066 (Praw=5.10×10−7, Pgenome=2.68×10−3) (Fig. 2a).
All signiﬁcant SNPs were located within a 7.2 Mb region on caninechromosome 7. A critical interval of 3.48 Mb (from 7.42838021 to
7.46320904) was delimited by recombinant chromosomes identiﬁed in
one EFS dog and an obligate carrier (Fig. 2b). In order to identify the
mutation associated with EFS, we prioritized several genes for
resequencing based on biological plausibility. These encoded ligand-
gated or voltage-gated ion channels (CHRNB2, HCN3, KCNN3), mito-
chondrial (MRPL24,MTSO1,MTX1, SLC25A44),muscle (MEF2D, TPM3) or
brain-expressed proteins (ARHGEF11, BCAN, GBA, HAPLN2, NES, RIT1,
SYT11, UBQLN4). Curiously, ampliﬁcation of BCAN exons 1, 2 and 3
consistently failed with multiple primer sets when using genomic DNA
from affected animals, while DNAs from carriers and unaffected dogs
ampliﬁed reliably (Fig. 3a). Because no preferential ampliﬁcation was
observed for the adjacent gene, HAPLN2—encoding hyaluronan and
proteoglycan link protein 2/Bral1 (Hirakawa et al., 2000; Oohashi et al.,
2002; Bekku et al., 2010)—we suspected that a microdeletion affecting
BCAN regulatory sequences and exons 1–3 was associated with EFS.
Deletion breakpoint identiﬁcation and development of diagnostic tests
Further primer walking experiments enabled us to clone and
sequence a DNA fragment containing the deletion breakpoint and
develop a multiplex PCR assay that distinguishes between affected,
carrier and normal dogs (Fig. 3b). Sequence analysis of the breakpoint
amplicon revealed a 15.7 kb microdeletion starting 1.56 kb down-
stream of HAPLN2, encompassing BCAN promoter elements and exons
1 (5′ untranslated), 2 and 3, ﬁnishing 85 bp downstream of BCAN exon
3 (Fig. 3c). The microdeletion amplicon also contained a 6 bp inserted
sequence (GGCCTT; Fig. 3d) typical of deletions resulting from non-
homologous end joining (NHEJ) or microhomology-mediated end
joining (MMEJ). Several regions of microhomology (1–7 bp) were
identiﬁed in a 30 bp region encompassing the breakpoints (Fig. 3e).
Fig. 3. (a) PCR panels for BCAN exons 1–4 showing that amplicons for the ﬁrst three exons of the brevican gene can be generated from genomic DNA from normal (+/+) or obligate
carrier (+/−) samples, but cannot be ampliﬁed from an equivalent EFS sample (−/−). By contrast, BCAN exon 4 can be ampliﬁed from all genotypes. (b) Multiplex PCRs with
primers ﬂanking the 15.7 kb BCAN microdeletion allowed simultaneous detection of the wild-type BCAN allele (primers EFS1+2, 393 bp) in normal (+/+) or EFS carrier (+/−)
animals, while the EFS allele (primers EFS1+3, 273 bp) is detected in both EFS carrier and affected (−/−) dogs. Note that the two carriers shown have both wild-type and EFS
amplicons, as expected for a heterozygous genotype. (c) Schematic diagram showing the genomic organization of the HAPLN2 and BCAN, the position of the deletion (grey shading)
and EFS1-3 primers. (d) Sequence spanning the BCAN deletion breakpoint, showing an additional non-homologous inserted sequence indicated by arrows. (e) Alignment of the DNA
sequence immediately ﬂanking the deletion breakpoint indicating local microhomology.
133J.L. Gill et al. / Neurobiology of Disease 45 (2012) 130–136Interestingly, 5 of the 6 bp of the reverse complemented inserted
sequence align to the largest region of microhomology. We also noted
an abundance of short interspersed element (SINE) insertions at the 5'Fig. 4. Position of the EFS microdeletion. Genomic DNA from canine chromosome 7 highlightend of the deleted sequence, which could cause the formation of
secondary structures that facilitate chromosomal rearrangement
(Chuzhanova et al., 2003). We also detected the presence of theing exons 1–4 of BCAN and the position of the 15.7 kb EFS microdeletion (grey shading).
Table 1
BCAN genotypes in CKCS cohorts and other dog breeds.
Phenotype Normal Carrier Affected
Study CKCS EFS affected 0/10 0/10 10/10
Study CKCS EFS carrier 0/8 8/8 0/8
Study CKCS related to affected or carrier 9/21 10/21 2/21
CKCS with no EFS history 135/155 20/155 0/155
54 dog breeds with no EFS history 93/93 0/93 0/93
Genotypes revealed by multiplex PCRs were determined as described in Materials and
methods. Dogs were evaluated on the basis of available clinical data and placed into one
of the phenotype categories above. Note that all clinically affected animals were
homozygous for the BCAN deletion, whilst obligate carriers were heterozygous. As well
as wild-type animals and carriers of the BCAN deletion, two dogs homozygous for the
BCAN deletion, which were not reported to have classical clinical signs of EFS, were
detected in a cohort of animals related to known EFS dogs. Carriers were also detected
in CKCS with no history of EFS, but not in control DNA samples from 54 other dog
breeds including: Airedale terrier, Akita Basenji, American Staffordshire Terrier,
American Cocker Spaniel, American Eskimo Dog, Australian Shepherd, Akita Basenji,
Bernese Mountain Dog, Bluetick Coonhound, Border Collie, Boston Terrier, Boxer,
Boykin Spaniel, Briard, Bull Mastiff, Bulldog, Cairn Terrier, Catahoula Leopard Dog,
Chihuahua, Collie, Dachshund, Dalmatian, English Setter, English Springer Spaniel, Flat
Coated Retriever, German Shepherd, Giant Schnauzer, Golden Retriever, Great Dane,
Havanese, Siberian Husky, Irish Setter, Italian Greyhound, Labrador Retriever,
Miniature Pinscher, Miniature Poodle, Miniature Schnauzer, New Guinea Singing
Dog, Norwegian Elkhound, Petit Basset Griffon Vendeen, Pomeranian, Portuguese
Podengo Pequeno, Pug, Pyrenean Shepherd, Schipperke, Shetland Sheepdog, Swedish
Vallhund, Tibetan Terrier, Toy Fox Terrier, Weimaraner, Welsh Terrier, West Highland
White Terrier, Wire Fox Terrier and Yorkshire Terrier. Where possible, two unrelated
dogs were tested for each breed.
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canine-speciﬁc probe sequences (Table S3). This quantitative analysis
also conﬁrmed that EFS is associated with a loss of BCAN
promoter/regulatory elements and exons 1–3 in heterozygous
carriers and homozygous affected animals (Fig. 5).
Rapid genotyping using multiplex genotyping in different dog populations
To assess the prevalence of the EFS microdeletion, we used our
multiplex PCR assay to test several CKCS populations and other dog
breeds (Table 1). All affected dogs in our study cohort—from the UK
(n=2), USA (n=6) and New Zealand (n=2), were homozygous for
the BCAN microdeletion. In addition, all obligate carriers were
heterozygous (n=2 from the USA and n=6 from New Zealand). In
animals related to affected dogs, we found 9 normal animals and 10
carriers. Interestingly, in this group, two dogs without a classical
clinical history of EFS were homozygous for the microdeletion. Lastly,
in dogs with no known clinical history of EFS sourced from the USA,
the carrier frequency was 12.9% (20/155) suggesting that the EFS
microdeletion is present at a high frequency in this population.
Notably, the mutation was not detected in multiplex PCRs conducted
on control DNA samples from 54 other breeds of dog (Table 1).
Discussion
The genomic architecture of pure-bred dog lines is ideal for the
identiﬁcation of loci responsible for autosomal recessive traits using
genome-wide association mapping (Karlsson et al., 2007; Drögemül-
ler et al., 2009). In this study, we demonstrate that this technique can
be used successfully on minimal samples sets, since we located the
EFS locus using DNA samples from only ﬁve affected and seven breed-
matched control dogs. Since a homozygous haplotype spanningFig. 5. Conﬁrmation of the BCAN microdeletion using Multiplex Ligation-dependent
Probe Ampliﬁcation. (a) MLPA analysis revealed robust detection of a control probe
(CFTRa) and probes for the BCAN promoter/regulatory region (PR) and exons 1–4.
However, signals for probes PR and exons 1–3 were reduced by 46–55% in
heterozygous (+/−) animals and abolished in homozygous animals (−/−), consistent
with a loss of probe binding sites in genomic DNA.6.35 Mb was identiﬁed in affected animals, it is questionable whether
further SNP typing would have generated additional useful data. In
fact, a single recombination event in an obligate carrier allowed us to
narrow the critical interval to 3.48 Mb. This region contained N100
genes, including ligand-gated ion channels, K+ channels, transporters,
mitochondrial proteins and several genes known to be involved in
neurological disorders in humans. For example, mutations in CHRNB2
are associated with nocturnal frontal lobe epilepsy (De Fusco et al.,
2000) and TPM3 mutations are associated with nemaline myopathy
(Laing et al., 1995). However, many of these genes were rapidly
eliminated as candidates due to either: i) poor correlation of EFS
clinical signs with the equivalent human disorders or ii) systematic
resequencing of the genes. Consistent with the unique clinical signs
observed in affected dogs, we discovered that a homozygous
microdeletion affecting BCAN is associated with EFS in CKCS dogs,
conﬁrming that this disorder is inherited in an autosomal recessive
manner. This mutation was not detected in control DNA samples from
54 other dog breeds, conﬁrming the unique nature of this genomic
rearrangement.
Brevican belongs to the lectican family of aggregating extracellular
matrix (ECM) proteoglycans, which comprises aggrecan, brevican,
neurocan and versican. Although mutations in the aggrecan and
versican genes (ACAN: 15q26.1 and VCAN: 5q14.2–14.3) have been
linked to different connective tissue disorders (Gleghorn et al., 2005;
Stattin et al., 2010; Miyamoto et al., 2005; Fig. 6), no mutations in the
brevican or neurocan genes (BCAN: 1q23.1 and NCAN: 19p13.11) have
been identiﬁed to date. Brevican and neurocan are highly expressed in
the central nervous system, where they are found in specialized
extracellular matrix structures called perineuronal nets that play a
role in cell adhesion, migration, axon guidance and neuronal plasticity
(Brakebusch et al., 2002). Brevican, versican, HAPLN2/BRAL1, tenas-
cin-R and phosphacan are also present at the nodes of Ranvier on large
diameter myelinated axons (Bekku et al., 2009, 2010) where cations
are accumulated and depleted in the local extracellular nodal region
during action potential propagation. The ECM complex at nodes of
Ranvier is thought to play a pivotal role in maintaining a local
microenvironment, acting as a diffusion barrier for K+ and Na+
around the perinodal extracellular space (Oohashi et al., 2002; Bekku
et al., 2010). Thus, disruption of ECM complexes governing synapse
Fig. 6. Modular organization of the superfamily of hyaluronan-binding proteins and
associated disorders. Mutations in ACAN, encoding aggrecan—a major component of
cartilage, have been implicated in spondyloepiphyseal dysplasia type Kimberley
(Gleghorn et al., 2005) and familial osteochondritis dissecans (Stattin et al., 2010).
Mutations in VCAN, encoding versican, are associatedwithWagner syndrome and erosive
vitreoretinopathy, disorders affecting the connective tissue of the eye (Miyamoto et al.,
2005). Modiﬁed fromMaeda et al., 2010.
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phenotype. Certainly, since EFS appears to result from a central
nervous system rather than a muscle defect, the associated sarco-
plasmic reticulum pathology is likely to be a secondary manifestation
of muscle overstimulation (Engel and Banker, 2004).
Interestingly,BCANknockoutmicewerenot reported (Brakebuschet
al., 2002) to have a phenotype similar to EFS - although an increased
grip-strength was noted, which could be indicative of increasedmuscle
tone. However, it is questionable whether current mouse phenotyping
tests will reveal neurological disorders evoked by strenuous exercise,
stress, apprehension or excitement, since these conditions are generally
avoided in mouse care. It is also noteworthy that EFS clearly shows
variable age of onset and penetrance. For instance, we identiﬁed two
dogs that were homozygous for the BCAN microdeletion that had not
shown classical clinical signs of EFS in the presence of their owners.
Interestingly, similar ﬁndings were reported for the dynamin (DNM1)
mutation (p.R256L) underlying exercise-induced collapse in Labrador
retrievers (Patterson et al., 2008). It is plausible that these dogs have not
been exposed to sufﬁcient exercise or excitement to trigger an episode,
or that genetic or environmental modifying factors (e.g. diet) affect the
onset of these disorders. However, it is notable that one of the two
asymptomatic dogs in our study was described as 'exercise resistant' by
their owner, suggesting that adaptive behavior may occur in dogs that
are homozygous for theBCANmicrodeletion. Itmust alsobeemphasized
that such non-classical cases are rare—we did not ﬁnd a single dog that
was homozygous for the BCAN microdeletion in 155 CKCS with no
family history of EFS (Table 1).
In summary, we have shown that an inactivating microdeletion
affecting BCAN is associated with EFS in CKCS dogs. Identiﬁcation of
the deletion breakpoint has allowed the development of diagnostic
tests that have revealed a high prevalence of carriers (12.9%) in
clinically unaffected dogs from the USA. These genetic tests (available
via Laboklin: http://www.laboklin.co.uk/) will enable future identiﬁ-
cation of heterozygous animals (which have no discernable pheno-
typic difference to wild-type animals) allowing directed breeding
programs to be implemented, and conﬁrmatory diagnosis and
appropriate pharmacotherapy of affected animals. Since this also
represents the ﬁrst report of a genetic disorder involving a neuronal-
speciﬁc ECM proteoglycan, we suggest that BCAN and NCAN should be
considered as candidate genes for genetic analysis in unresolved cases
of human disorders with similar clinical presentations to EFS, such asparoxysmal exercise-induced dyskinesias (Weber and Lerche, 2009)
or episodic ataxias (Tomlinson et al., 2009).
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